Amsterdam-listed Odyssey has agreed to buy BenevolentAI in a deal valuing the British-based pharmaceuticals firm at up to 1.5 billion euros (US$1.7 billion) after the transaction, the biggest acquisition by a European special purpose acquisition vehicle to date, Reuters reports. Read more.
Odyssey Buys Drugmaker BenevolentAI in Europe’s Biggest SPAC Deal
